
    
      This is a Phase I, 7-day, randomized, double-blind, placebo-controlled, multiple ascending
      dose study of orally administered ALLN-346 in normal healthy volunteers. Study will take
      place at a clinical pharmacology unit (CPU). Two sequential cohorts will be dosed and
      followed for safety through Day 28.

      The study will evaluate safety and tolerability (including inflammation and immunogenicity),
      and pharmacodynamics of ALLN-346.
    
  